Fc Receptor-like 5, Recombinant, Human (FCRL5, FcRH5)
Biozol Catalog Number:
USB-F0025-77
Supplier Catalog Number:
F0025-77
Alternative Catalog Number:
USB-F0025-77-50
Manufacturer:
US Biological
Category:
Molekularbiologie
Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120kD protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-l i ke domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation. According to testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836aa extracellular domain (ECD) with nine Ig-like domains, a 21aa transmembrane segment, and a 105aa cytoplasmic domain with one immunotyrosine activation motif (ITAM) and two immunotyrosine inhibitory motifs (ITIMs). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains. FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood. Its ligation inhibits signaling through the B cell antigen receptor. Epstein-Barr virus transformation of B cells induces the upregulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription. The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities. FCRL5 is upregulated on tumor cells in some types of B cell malignancies. In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients. Recombinant protein corresponding to Gln16-Arg844 with a C-Terminal 6-His-Tag from human FCRL5, expressed in NS0 cells. Swiss/UniProt Accession: AAK93971 SDS-PAGE: 110-120kD, reducing conditions Biological Activity: Measured by its ability to bind human IgG with an estimated KD <30nM Storage and Stability: Lyophilized and reconstituted products are stable for 6 months after receipt at -70C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -70C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
